Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 200,000 shares at $35.63 ($7.2M) on 2026-08-28, disclosed to the SEC on 2026-09-01.
Scheduled sale ($7.2M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.63 | 166,182 | $5.9M | 82.8% |
| 2 | $36.44 | 33,818 | $1.2M | 17.2% |
| Total | $35.77 avg | 200,000 | $7.2M | 100% |
| Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |
| ROIV | SELL | 2026-06-26 | $6.6M | — | Filing → |